carbostyril has been researched along with Salivary Gland Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, R; Brose, M; Chau, NG; Cohen, EEW; Gualberto, A; Guenette, JP; Hanna, GJ; Ho, AL; Metcalf, R; Pérez-Ruiz, E; Razaq, M; Sayehli, CM; Scholz, C; Wilhelm, C; Wong, DJ | 1 |
| Bang, YJ; Cho, BC; Keam, B; Kim, MK; Kim, SB; Lee, KW; Lee, SH; Shin, SH; Yoon, DH; Yun, HJ | 1 |
2 trial(s) available for carbostyril and Salivary Gland Neoplasms
| Article | Year |
|---|---|
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Topics: Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Progression-Free Survival; Proto-Oncogene Proteins p21(ras); Quinolones; Salivary Gland Neoplasms; Treatment Outcome | 2020 |
Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Adenoid Cystic; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Republic of Korea; Salivary Gland Neoplasms; Treatment Outcome; Young Adult | 2015 |